Neurology News and Research

Latest Neurology News and Research

Dantrolene may help combat Duchenne muscular dystrophy in boys

Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.

13 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Researchers discover a trigger by which the HCV enters liver cells

Researchers at the University of Southern California (USC) have discovered a trigger by which the Hepatitis C virus enters liver cells ─ shedding light on how this serious and potentially deadly virus can begin to damage the liver.

13 Dec 2012

AC253 drug appears to restore memory in Alzheimer's brain cells

Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.

11 Dec 2012

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Dementia is the umbrella term used to describe a number of neurodegenerative brain disorders that cause progressive changes in thinking abilities and behaviour. The kind of deficits experienced by individuals diagnosed with dementia depends on the location and severity of the pathology in the brain.

11 Dec 2012

Recurrence unlikely in childhood cryptogenic stroke

Children with cryptogenic stroke, including that associated with previous varicella infection, are very unlikely to have a recurrence, report researchers.

11 Dec 2012

Cedars-Sinai first in Los Angeles County to achieve Comprehensive Stroke Center Certification

Cedars-Sinai is one of the first five medical centers in the nation and the first in Los Angeles County to achieve Comprehensive Stroke Center Certification from The Joint Commission and the American Heart Association/American Stroke Association.

11 Dec 2012

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

A nanomaterial engineered by researchers at Duke can help regulate chloride levels in nerve cells that contribute to chronic pain, epilepsy, and traumatic brain injury.

11 Dec 2012

Traumatic brain injury incidence: an interview with Professor Valery Feigin

Traumatic brain injury can be defined as an injury to the brain due to mechanical forces. Mechanical forces usually include falls, car accidents, accidental forces from another person or animal. It also includes sports-related brain injuries.

11 Dec 2012

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Researchers at Mayo Clinic in Florida have uncovered a toxic cellular process by which a protein that maintains the health of neurons becomes deficient and can lead to dementia.

11 Dec 2012

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

FoxP3 gene expression identifies ALS disease progression in 80% of patients

The debilitating symptoms of amyotrophic lateral sclerosis, or ALS, appear to be increased by a lack of inflammation-reducing T cells, report scientists from the Methodist Neurological Institute in an upcoming print issue of The EMBO Molecular Medicine Journal.

10 Dec 2012

Anti-seizure drug benefits women with severe morning sickness

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

8 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

Drug offers alternative treatment strategy for insomnia

Orexin receptor antagonism may offer a novel treatment approach to insomnia, clinical findings suggest.

7 Dec 2012

Disturbances in several immune-system-related pathways contribute to development of ASDs

Researchers using novel approaches and methodologies of identifying genes that contribute to the development of autism have found evidence that disturbances in several immune-system-related pathways contribute to development of autism spectrum disorders.

7 Dec 2012

Advance Study to evaluate safety and benefit of DBS-f for patients with mild Alzheimer's

The first U.S. patient to enroll in Functional Neuromodulation's ADvance Study was successfully implanted with a deep brain stimulation (DBS) system. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain's memory circuit, for patients with mild Alzheimer's.

7 Dec 2012

Kessler Foundation to study effects of intellectual enrichment on cognitive decline in people with MS

The National Multiple Sclerosis (MS) Society awarded Victoria Leavitt, Ph.D., a $44,000 grant to study the effects of intellectual enrichment on cognitive decline in individual with multiple sclerosis.

7 Dec 2012

Neurology News and Research

Latest Neurology News and Research

Dantrolene may help combat Duchenne muscular dystrophy in boys

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Researchers discover a trigger by which the HCV enters liver cells

AC253 drug appears to restore memory in Alzheimer's brain cells

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Recurrence unlikely in childhood cryptogenic stroke

Cedars-Sinai first in Los Angeles County to achieve Comprehensive Stroke Center Certification

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

Traumatic brain injury incidence: an interview with Professor Valery Feigin

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

FoxP3 gene expression identifies ALS disease progression in 80% of patients

Anti-seizure drug benefits women with severe morning sickness

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Drug offers alternative treatment strategy for insomnia

Disturbances in several immune-system-related pathways contribute to development of ASDs

Advance Study to evaluate safety and benefit of DBS-f for patients with mild Alzheimer's

Kessler Foundation to study effects of intellectual enrichment on cognitive decline in people with MS

Neuroscience - Third Edition eBook

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Neurology News and Research

Latest Neurology News and Research

Neuroscience - Third Edition eBook

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Newsletters you may be interested in